$1 Million To Fund Head And Neck Cancer Chair At The James

June 17, 2011

COLUMBUS, Ohio – Two siblings are honoring their deceased parents by pledging $1 million to create an endowed chair in head and neck cancer research at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).

Ron Alford of Westerville, Ohio, along with his sister Barb Cantlin and her husband Mike of Newark, Ohio, have pledged the additional funding over the next four years.

Their $1 million pledge adds to the original $500,000 donation made by John Alford to create the first research endowment at The James shortly after the free-standing cancer hospital opened in July 1990.

After his wife died of stomach cancer in 1987, John Alford chose to honor her memory by creating the Mary E. Alford Cancer Research Endowment Fund for cancer research at The James. When John Alford died of esophageal cancer in 1996, his children donated an additional $500,000 to create the Mary E. and John W. Alford Cancer Research Endowment Fund at The James.

With the latest gift pledge, once the fund reaches $2 million it will be renamed the Mary E. and John W. Alford Research Chair in Head and Neck Cancer.

"The level of support shown by the Alford family through the years to The James is a testament to their lifelong mission of trying to improve and enhance the lives of others," says Dr. Michael Caligiuri, director of Ohio State's Comprehensive Cancer Center and CEO of The James. "This additional funding will allow us to attract the best and the brightest to join the elite team of our stellar head and neck cancer program."

Part of the funding will come from the Alford Family Foundation, which is operated by Ron Alford and Barb Cantlin and primarily supports organizations in Licking County, where John and Mary raised their family in Newark, Ohio, during their 36-year marriage.

"Our Dad always had a love of the Buckeyes and he had an allegiance to the university. My father was very giving, and the last 10 years of his life he was known more as a philanthropist than as a banker," says Ron Alford, who last year was successfully treated at The James for cancer of the larynx.

John Alford was a prominent banker in Licking County, where he rose through the ranks at Park National Bank, eventually becoming director, president, CEO and chairman of the executive committee. He also served as president of the Ohio Banker's Association and was a member of the Cleveland Federal Reserve Board and the Visa International Board.

"We look at this gift as a tribute to our parents, and we are proud that the gift will support cancer research at The James," says Barb Cantlin. "We always try to give back to Licking County, and there is a clear connection with this gift. We know that plenty of people in Licking County have benefitted from The James. Daddy always taught us to give back."

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (cancer.osu.edu) is one of only 40 Comprehensive Cancer Centers in the United States designated by the National Cancer Institute. Ranked by U.S. News & World Report among the top cancer hospitals in the nation, The James is the 205-bed adult patient-care component of the cancer program at The Ohio State University. The OSUCCC – James is one of only seven centers in the country funded by the NCI to conduct both phase I and phase II clinical trials.

# # #

Contact: Eileen Scahill, Medical Center Public Affairs and Media Relations, 614-293-3737, or Eileen.Scahill@osumc.edu

Contact Media Staff

Amanda Harper

Director of Media Relations

614-685-5420 (direct)

614-293-3737 (main)


Media staff are available by calling 614-293-3737 Monday through Friday between 8 a.m. and 5 p.m.


If after hours, please call 614-293-8000 (ask the operator to page the hospital administrative manager).

Latest News

Drug Harnesses Immune System To Combat Most Common Form of Lung Cancer

Recently approved immunotherapy drugs are offering patients – and their oncologists – new hope for extending survival of people with advanced non-small cell lung cancer (NSCLC).

Investigational Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers

New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health. The experimental agent, known as AR-42 while in...

One Day to Help Create More Healthy — And Cancer-Free — Tomorrows

Through the generous support of Don and Angie Ward, all donations made to Ohio State's cancer program today (Nov. 24) through Giving Tuesday (Dec. 1), will be matched, 100 percent, up to $50,000.